New drug targets Hard-to-Treat cancers with MET mutations
Disease control
Ongoing
This early-phase study tests a new drug called TPX-0022 in adults with advanced lung, stomach, or other solid tumors that have specific MET gene changes. The main goals are to check the drug's safety, find the best dose, and see if it shrinks tumors. About 95 participants will ta…
Phase: PHASE1 • Sponsor: Turning Point Therapeutics, Inc. • Aim: Disease control
Last updated May 22, 2026 13:50 UTC